Safety of Infusing Rituximab at a More Rapid Rate in Patients with Rheumatoid Arthritis: Results from the RATE-RA Study
BioMed Central Musculoskeletal Disorders
Geisel School of Medicine
As recommended in the current prescribing information, rituximab infusions in patients with rheumatoid arthritis (RA) take 4.25hours for the first infusion and 3.25hours for subsequent infusions, which is a burden on patients and the health care system. We therefore evaluated the safety of infusing rituximab at a faster rate for an infusion period of 2hours in patients with RA.
Dartmouth Digital Commons Citation
Pritchard, Charles H.; Greenwald, Maria W.; Kremer, Joel M.; Gaylis, Norman B.; and Rigby, William, "Safety of Infusing Rituximab at a More Rapid Rate in Patients with Rheumatoid Arthritis: Results from the RATE-RA Study" (2014). Dartmouth Scholarship. 654.
Musculoskeletal Diseases Commons, Rehabilitation and Therapy Commons, Rheumatology Commons